ClinicalTrials.gg
CompletedNCT00063726Updated Jan 13, 2012

A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

A Phase 3 interventional study of bortezomib in Multiple Myeloma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 76 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-13.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
8th of 267
600 · median 41
Started
2002
with 1 other
Phase 3
42 of 271
1 open now
Registered
5th of 271
by date
Lead sponsor
6 of 271
Millennium Pharmaceuticals, Inc.

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 8th largest by enrollment of the 267 interventional ones that give a count, is one of 2 that started in 2002, is one of 42 in phase 3, and was the 5th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to allow patients to receive VELCADE™ (bortezomib) for Injection who experienced progressive disease(PD) while receiving high-dose dexamethasone from the M34101-039 study.

Read the detailed description

The rationale for Amendment 2 is 2-fold. First, it is intended that this study serve as a rollover protocol for patients who experience progressive disease (PD) after receiving the comparator treatment, high-dose dexamethasone, in MPI Study M34101-039, thereby ultimately providing all patients who participate in Study M34101-039 and require treatment for their disease access to VELCADE™ (bortezomib) for Injection, formerly known as MLN341, LDP-341 and PS-341.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient experienced PD, as defined by SWOG+ criteria during or after treatment with high-dose dexamethasone in MPI Study M34101-039, but has not received alternate anti-neoplastic therapy. Intolerance to high-dose dexamethasone therapy as administered in MPI study M34101-039 does not qualify as PD.
  • Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.
  • Patient has given voluntary written before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
  • Female patient is , surgically sterilized, or willing to use acceptable methods of (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) from Screening through the End of Treatment visit.
  • Male patient agrees to use an acceptable barrier method for contraception from Screening through the End of Treatment visit.
  • Patient meets the following pretreatment laboratory criteria at and within 14 days before Baseline (Day 1 of Cycle 1, before study drug administration). (Note that the End of Treatment assessments of MPI study M34101-039 may qualify as the Screening assessments for MPI study M34101-040 if performed within 14 days of the Baseline visit.):
  • count ≥20 X 10E+9/L, with or without transfusion support.
  • ≥7.0 g/dL, with or without transfusion support.
  • (ANC)≥0.5 x 10E+9/L, without growth factor support.
  • Serum calcium \<14 mg/dL (3.5 mmol/L).
  • (AST):≤2.5 x the (ULN).
  • Alanine transaminase (ALT):≤2.5 x the ULN.
  • Total :≤1.5 x the ULN.
  • If calculated or measured : ≥20 mL/minute, assessments are as specified in the protocol. If calculated or measured creatinine clearance is \<20 mL/minute.

Exclusion criteria

Exclusion Criteria

  • Patient participated in M34101-039 and did not have confirmed PD. Dexamethasone intolerance does not qualify as PD.
  • Patient had PD on the dexamethasone arm of the MPI Study M34101-039, and then received alternate anti-neoplastic therapy.
  • Patient has not recovered from dexamethasone-related toxicity experienced during MPI Study M34101-039.
  • Patient is known to be (HIV)-positive.(Patients assessed by the investigator to be at risk for HIV infection should be tested in accordance with local regulations.)
  • Patient is known to be surface antigen-positive or has known active infection.(Patients assessed by the investigator to be at risk for hepatitis B or C infection should be tested in accordance with local regulations.)
  • Female patient is pregnant or breast-feeding.
  • Patient developed a new or experienced worsening of an existing illness during or after completion of Study M34101-039 that, in the investigator's opinion, may put the patient at risk of participation in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
600 participants

Interventions

06

Study locations

76 sites
  • University of Arkansas Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Alta Bates Comprehensive Cancer Center
    Berkeley, California 94704, United States
  • City of Hope
    Duarte, California 91010, United States
  • Scripps Clinic, Green Cancer Center
    La Jolla, California 92307, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • Kaiser Permanente Medical Center
    Vallejo, California 94589, United States
  • Lombardi Cancer Center, Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Med Star Institute
    Washington, District of Columbia 20010, United States
  • Hematology/Oncology Associates, PA
    Jacksonville, Florida 32207, United States
  • University of Miami
    Miami, Florida 33136, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University Medical School
    Chicago,, Illinois 60611, United States
  • Loyola University Medical Center: Cardinal Bernardin Cancer Center
    Maywood, Illinois 60153, United States
  • LSU HC
    Sheveport, Louisiana 71130, United States
  • Tufts England Medical Center
    Boston, Massachusetts 02111, United States
  • Mass General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Center
    Boston, Massachusetts 02115, United States
  • Univ. of Michigan Comp. Cancer Center,
    Ann Arbor, Michigan 48109-0922, United States
  • VA Medical Center
    Minneapolis, Minnesota 55417, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Hackensack University Medical Center, David Jurist Research Building
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Long Island Jewish Medical Center
    New Hyde Park, New York 11040, United States
  • St. Vincent's Comprehensive Cancer Center
    New York, New York 10011, United States
  • Weill Medical College of Cornell University, NY Presbyterian Hospital
    New York, New York 10021, United States
  • Rochester General Hospital
    Rochester, New York 14621, United States
  • University of Rochester Medical Center, James P. Wilmot Cancer Center
    Rochester, New York 14642, United States
  • Charlotte Hematology Oncology Associates
    Charlotte, North Carolina 28203, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania Cancer Center
    Philadelphia,, Pennsylvania 19104, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Trident Palmetto Hematology/Oncology
    Charleston, South Carolina 29406, United States
  • Division of Hematology/Stem Cell Transplant
    Nashville, Tennessee 37232-5505, United States
  • Texas Oncology at Medical City Dallas Hospital
    Dallas, Texas 75225, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Wilhelminenspital Wien, Abt. Fur Med. und Medizinische Onkologie
    Wien, 1171, Austria
  • ACZA, Campus Stuivenberg
    Antwerpen, 2060, Belgium
  • AZ St. Jan, Dept of Haematology
    Brugge, 8000, Belgium
  • CHU Erasme / ULB University
    Brussels, 1070, Belgium
  • Institue Jules Bordet, Unite Sterile
    Bruxelles, 1000, Belgium
  • C.H. Notre Dame-Reine Fabiola, Department d'Oncologie et Hematolgie
    Charleroi, 6000, Belgium
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • London Health Sciences Center
    London, Ontario N6A 4G5, Canada
  • Toronto General Research Institute
    Toronto, Ontario M5G2M9, Canada
  • McGill University Clinical Research Program
    Montreal, Quebec H2W 1S6, Canada
  • Hospital Claude Huriez
    Lile, Cedex 59037, France
  • Hoptial Hotel Dieu
    Paris, Cedex 75181, France
  • Hopital Purpan, Pavillon Dieulafoy, Service d'Hematologie Clinique
    Toulouse, Cedex 31059, France
  • Hopital de Brabois
    Vandoeuvre, Cedex 54511, France
  • Centre Hospitalier Lyon Sud
    Cedex, 69495, France
  • Hopital Antoine Beclere
    Clamart, 92140, France
  • Hospital Saint-Louis
    Paris, 75010, France
  • Universitatsklinikum Charite Medizinische Klinik und Poliklinik
    Berlin, 10098, Germany
  • Medizinsche Klinik und Poliklinik 1, Rheinische Friedrich-Wilhelms-Universitaet
    Bonn, 53127, Germany
  • University of Erlangen-Nurenberg, Division of Hematology/Oncology
    Erlangen, 91054, Germany
  • Medical University Clinic (Oncology/Haematology)
    Hamburg, 20246, Germany
  • Universitatsklinikum Heidelberg
    Heidelberg, 69115, Germany
  • Johannes-Gutenberg-University Medical School, Department of Medicine III
    Mainz, 55101, Germany
  • Uniklinikum Muenster, Medizinische Klinik und Poliklinik A
    Muenster, 48129, Germany
  • Belfast City Hospital, Haematology Department
    Belfast, BT9 7AB, Ireland
  • Hadassah University Hospital
    Jerusalem, 91120, Israel
  • Dipartimento di Biotecnologie Cellulari ed Ematologia, Az. Policlinico Umberto 1
    Roma, 00161, Italy
  • Azienda Ospedaliera, S. Giovanni Battista
    Torino, 10126, Italy
  • Erasmus MC, 1a, Daniel Den Hoed, Department of Hematology
    Rotterdam, 3075, Netherlands
  • Hospital Clinico Universitario de Barcelona, Hematologia
    Barcelona, 08036, Spain
  • University Hospital of Salamanca, Hematology Dept
    Salamanca, 37007, Spain
  • Huddinge University Hospital M54, Department of Haematology
    Stockholm, 14186, Sweden
  • Adult Leukaemia Unit, Christie Hospital
    Withington, Manchester M20 4BX, United Kingdom
  • Queen Elizabeth Hospital
    Birmingham, B15 2TH, United Kingdom
  • Leeds General Infirmary, Department of Haematology
    Leeds, LS1 3EX, United Kingdom
  • Department of Haematology, ICSM
    London, W12 0NN, United Kingdom
  • Royal Marsden Hospital
    Sutton, SM2 5PT, United Kingdom
07

References and documents

Publications

  • van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WC, van der Holt B, Joseph-Pietras D, Mulligan G, Neuwirth R, Sahota SS, Sonneveld P. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica. 2011 Nov;96(11):1662-9. doi: 10.3324/haematol.2010.037978. Epub 2011 Jul 26. PubMed 21791470 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2002, a primary completion of May 2005 and a completion of Jul 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2003
First posted
Jul 11, 2003
Start
Apr 2002
Primary completionActual
May 2005
CompletionActual
Jul 2005
Last update
Jan 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00063726
First posted
Jul 11, 2003
Start date
Apr 2002
Primary completion
May 2005
Completion
Jul 2005
Last update
Jan 13, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion